Biomarker Development and Preemptive Therapy of Alzheimer's Disease
update：2020-06-16
Features
Over the past 20 years, our understanding of molecular pathology of dementia and AD has dramatically deepened, and new biomarkers including amyloid PET and cerebrospinal fluid (CSF) amyloid42/tau as well as therapeutic strategies have been developed. However, clinical trials of disease-modifying drugs in mild to moderate AD were unsuccessful or were halted due to serious adverse drug effects.Targeted Application(s)/Industry
These results strongly suggest that disease-modifying therapies should be started much earlier before a widespread neuron death will occur. We hope that early detection and prevention with preemptive therapy may lead to a success of fighting AD.Researchers
Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer
ARAI Hiroyuki
, Professor
MD, PhD
Keywords
Prev
List
Next